Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Portfolio Pulse from Vandana Singh
Acuitas Therapeutics has filed a lawsuit against CureVac SE, alleging that CureVac failed to credit Acuitas on patents for COVID-19 vaccine technology. Acuitas claims its lipid nanoparticle technology was used in the Pfizer/BioNTech vaccine and seeks to be listed as co-inventors on CureVac patents. Pfizer and BioNTech have also sued CureVac over infringement allegations. CureVac is testing a modified COVID-19 vaccine with GSK and expects study data in early 2024. CVAC shares closed at $5.66.
November 15, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech SE, in partnership with Pfizer, is involved in a legal dispute with CureVac SE over COVID-19 vaccine technology. BioNTech's vaccine uses Acuitas's lipid nanoparticle technology.
BioNTech's involvement in the lawsuit with CureVac may have a neutral short-term impact on its stock, given its strong position in the COVID-19 vaccine market.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
GSK Plc is collaborating with CureVac SE on testing a modified COVID-19 vaccine, with a study data read-out expected in early 2024.
GSK's collaboration with CureVac on vaccine development is a forward-looking project, and the current legal issues may not significantly impact GSK's stock in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Pfizer Inc, along with BioNTech, has sued CureVac SE, asking a judge to block CureVac's infringement allegations against the companies. Pfizer's vaccine technology is partly based on Acuitas's lipid nanoparticle technology.
While the lawsuit adds a layer of complexity, Pfizer's established market position and diversified portfolio may mitigate the short-term impact on its stock price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
CureVac SE faces a lawsuit from Acuitas Therapeutics over patent credits for COVID-19 vaccine technology and is also being sued by Pfizer and BioNTech. The company is confident in its IP and is currently testing a modified vaccine with GSK.
The lawsuit from Acuitas and the ongoing legal battle with Pfizer and BioNTech could negatively impact investor sentiment and CureVac's stock price in the short term due to potential financial and reputational risks.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100